RVT-101: Phase IIb data

Data from patients who had complete data at each visit in a double-blind, international Phase IIb trial showed that 35 mg RVT-101 plus Aricept donepezil significantly improved ADAS-Cog score from baseline by 1.29 points at week 12 (p=0.008), 1.63 points at week 24 (p=0.007), 1.35 points at week 36 (p=0.039) and 1.82 points at week 48 (p=0.018) relative to placebo. RVT-101 plus Aricept also significantly improved ADCS-ADL score from baseline by 1.72 points at week 12 (p=0.016), 2.11 points at week 24 (p=0.016), 2.2 points at week 36 (p=0.029) and 2.34 points at week 48 (p=0.048) relative to placebo. Additionally, RVT-101 plus Aricept led to a significant improvement in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score from baseline to week 12 vs. placebo, but only numerical improvements at other time points. ...